Journal of the Neurological Sciences
Volume 287, Issue 1 , Pages 17-26 , 15 December 2009

Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis

  • Lorenzo De Santi

      Affiliations

    • IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy
    • Corresponding Author InformationCorresponding author. IRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy. Tel.: +39 090 3656756; fax: +39 090 3656750.
    • ,
  • Pasquale Annunziata

      Affiliations

    • Department of Neurological, Neurosurgical and Behavioural Sciences, University of Siena, Siena, Italy
    • ,
  • Edoardo Sessa

      Affiliations

    • IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy
    • ,
  • Placido Bramanti

      Affiliations

    • IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy

Received 24 April 2009 ,Revised 24 August 2009 ,Accepted 27 August 2009.

References 

  1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–1517
  2. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683–747
  3. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278–285
  4. Brück W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol. 2005;252(Suppl):5v3–9
  5. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci. 2003;206(2):165–171
  6. Rieckmann P, Mäurer M. Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis. Curr Opin Neurol. 2002;15(3):361–370
  7. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med. 1999;5(1):49–55
  8. Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol. 2003;53(3):292–304
  9. Graber JJ, Dhib-Jalbut S. Protective autoimmunity in the nervous system. Pharmacol Ther. 2009;121(2):147–159
  10. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?. J Exp Med. 1999;189(5):865–870
  11. Stadelmann C, Kerschensteiner M, Misgeld T, Brück W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?. Brain. 2002;125(Pt 1):75–85
  12. Ziemssen T, Kümpfel T, Klinkert WEF, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain. 2002;125(Pt 11):2381–2391
  13. Chen M, Valenzuela RM, Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci. 2003;215(1–2):37–44
  14. Makar TK, Bever CT, Singh IS, Royal W, Sahu SN, Sura TP, et al. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J Neuroimmunol. 2009;210(1–2):40–51
  15. Sarchielli P, Zaffaroni M, Floridi A, Greco L, Candeliere A, Mattioni A, et al. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Mult Scler. 2007;13(3):313–331
  16. Cowan WM. Viktor Hamburger and Rita Levi-Montalcini: the path to the discovery of nerve growth factor. Annu Rev Neurosci. 2001;24551–24600
  17. Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, et al. Molecular cloning and expression of brain-derived neurotrophic factor. Nature. 1989;341(6238):149–152
  18. Bauer S, Kerr BJ, Patterson PH. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci. 2007;8(3):221–232
  19. Baloh RH, Enomoto H, Johnson EM, Milbrandt J. The GDNF family ligands and receptors — implications for neural development. Curr Opin Neurobiol. 2000;10(1):103–110
  20. Lindvall O, Kokaia Z, Bengzon J, Elmér E, Kokaia M. Neurotrophins and brain insults. Trends Neurosci. 1994;17(11):490–496
  21. Seidah NG, Benjannet S, Pareek S, Chrétien M, Murphy RA. Cellular processing of the neurotrophin precursors of NT3 and BDNF by the mammalian proprotein convertases. FEBS Lett. 1996;379(3):247–250
  22. Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M. Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol. 1989;9(1):24–33
  23. Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature. 1991;350(6314):158–160
  24. Klein R, Nanduri V, Jing SA, Lamballe F, Tapley P, Bryant S, et al. The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell. 1991;66(2):395–403
  25. Arévalo JC, Wu SH. Neurotrophin signaling: many exciting surprises!. Cell Mol Life Sci. 2006;63(13):1523–1537
  26. Tacconelli A, Farina AR, Cappabianca L, Desantis G, Tessitore A, Vetuschi A, et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell. 2004;6(4):347–360
  27. Klein R, Conway D, Parada LF, Barbacid M. The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. Cell. 1990;61(4):647–656
  28. Stoilov P, Castren E, Stamm S. Analysis of the human TrkB gene genomic organization reveals novel TrkB isoforms, unusual gene length, and splicing mechanism. Biochem Biophys Res Commun. 2002;290(3):1054–1065
  29. Eide FF, Vining ER, Eide BL, Zang K, Wang XY, Reichardt LF. Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J Neurosci. 1996;16(10):3123–3129
  30. Liepinsh E, Ilag LL, Otting G, Ibáñez CF. NMR structure of the death domain of the p75 neurotrophin receptor. EMBO J. 1997;16(16):4999–5005
  31. Teng HK, Teng KK, Lee R, Wright S, Tevar S, Almeida RD, et al. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci. 2005;25(22):5455–5463
  32. Copray S, Küst B, Emmer B, Young Lin M, Liem R, Amor S, et al. Deficient p75 low-affinity neurotrophin receptor expression exacerbates experimental allergic encephalomyelitis in C57/BL6 mice. J Neuroimmunol. 2004;148(1–2):41–53
  33. Küst B, Mantingh-Otter I, Boddeke E, Copray S. Deficient p75 low-affinity neurotrophin receptor expression does alter the composition of cellular infiltrate in experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuroimmunol. 2006;174(1–2):92–100
  34. Bayas A, Hummel V, Kallmann BA, Karch C, Toyka KV, Rieckmann P. Human cerebral endothelial cells are a potential source for bioactive BDNF. Cytokine. 2002;19(2):55–58
  35. Ruprecht K, Stadelmann C, Hummel V, Klein O, Brück W, Rieckmann P. Brain derived neurotrophic factor does not act on adult human cerebral endothelial cells. Neurosci Lett. 2002;330(2):175–178
  36. Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science. 2001;294(5548):1945–1948
  37. Hempstead BL. The many faces of p75NTR. Curr Opin Neurobiol. 2002;12(3):260–267
  38. Besser M, Wank R. Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol. 1999;162(11):6303–6306
  39. De Santi L, Cantalupo L, Tassi M, Raspadori D, Cioni C, Annunziata P. Higher expression of BDNF receptor gp145trkB is associated with lower apoptosis intensity in T cell lines in multiple sclerosis. J Neurol Sci. 2009;277(1–2):65–70
  40. Edling AE, Nanavati T, Johnson JM, Tuohy VK. Human and murine lymphocyte neurotrophin expression is confined to B cells. J Neurosci Res. 2004;77(5):709–717
  41. Yamamoto H, Gurney ME. Human platelets contain brain-derived neurotrophic factor. J Neurosci. 1990;10(11):3469–3478
  42. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 1996;19(11):514–520
  43. Schuhmann B, Dietrich A, Sel S, Hahn C, Klingenspor M, Lommatzsch M, et al. A role for brain-derived neurotrophic factor in B cell development. J Neuroimmunol. 2005;163(1–2):15–23
  44. Bratke K, Maruschke L, Darowski M, Kuepper M, Braun A, Virchow JC, et al. A role for the neurotrophin receptor TrkB on maturing dendritic cells. J Neuroimmunol. 2007;189(1–2):88–94
  45. Maroder M, Bellavia D, Meco D, Napolitano M, Stigliano A, Alesse E, et al. Expression of trKB neurotrophin receptor during T cell development. Role of brain derived neurotrophic factor in immature thymocyte survival. J Immunol. 1996;157(7):2864–2872
  46. Garcia-Suarez O, Blanco-Gelaz MA, Lopez ML, Germana A, Cabo R, Díaz-Esnal B, et al. Massive lymphocyte apoptosis in the thymus of functionally deficient TrkB mice. J Neuroimmunol. 2002;129(1–2):25–34
  47. Berzi A, Ayata CK, Cavalcante P, Falcone C, Candiago E, Motta T, et al. BDNF and its receptors in human myasthenic thymus: implications for cell fate in thymic pathology. J Neuroimmunol. 2008;197(2):128–139
  48. Laurenzi MA, Barbany G, Timmusk T, Lindgren JA, Persson H. Expression of mRNA encoding neurotrophins and neurotrophin receptors in rat thymus, spleen tissue and immunocompetent cells. Regulation of neurotrophin-4 mRNA expression by mitogens and leukotriene B4. Eur J Biochem. 1994;223(3):733–741
  49. Lomen-Hoerth C, Shooter EM. Widespread neurotrophin receptor expression in the immune system and other nonneuronal rat tissues. J Neurochem. 1995;64(4):1780–1789
  50. Labouyrie E, Dubus P, Groppi A, Mahon FX, Ferrer J, Parrens M, et al. Expression of neurotrophins and their receptors in human bone marrow. Am J Pathol. 1999;154(2):405–415
  51. Hannestad J, Levanti MB, Vega JA. Distribution of neurotrophin receptors in human palatine tonsils: an immunohistochemical study. J Neuroimmunol. 1995;58(2):131–137
  52. García-Suárez O, Hannestad J, Esteban I, Martínez del Valle M, Naves FJ, Vega JA. Neurotrophin receptor-like protein immunoreactivity in human lymph nodes. Anat Rec. 1997;249(2):226–232
  53. Schenone A, Gill JS, Zacharias DA, Windebank AJ. Expression of high- and low-affinity neurotrophin receptors on human transformed B lymphocytes. J Neuroimmunol. 1996;64(2):141–149
  54. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 2004;430(7003):1034–1039
  55. Li Z, Beutel G, Rhein M, Meyer J, Koenecke C, Neumann T, et al. High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood. 2009;113(9):2028–2037
  56. Feng X, Jiang H, Baik JC, Edgar C, Eide FF. BDNF dependence in neuroblastoma. J Neurosci Res. 2001;64(4):355–363
  57. Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL. A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood. 2005;105(11):4429–4436
  58. Gravel C, Götz R, Lorrain A, Sendtner M. Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons. Nat Med. 1997;3(7):765–770
  59. McTigue DM, Horner PJ, Stokes BT, Gage FH. Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J Neurosci. 1998;18(14):5354–5365
  60. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128(Pt 11):2705–2712
  61. Kil K, Zang YC, Yang D, Markowski J, Fuoco GS, Vendetti GC, et al. T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. J Neuroimmunol. 1999;98(2):201–207
  62. Bieber AJ, Kerr S, Rodriguez M. Efficient central nervous system remyelination requires T cells. Ann Neurol. 2003;53(5):680–684
  63. Tobias CA, Shumsky JS, Shibata M, Tuszynski MH, Fischer I, Tessler A, et al. Delayed grafting of BDNF and NT-3 producing fibroblasts into the injured spinal cord stimulates sprouting, partially rescues axotomized red nucleus neurons from loss and atrophy, and provides limited regeneration. Exp Neurol. 2003;184(1):97–113
  64. Schwartz M, Moalem G, Leibowitz-Amit R, Cohen IR. Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci. 1999;22(7):295–299
  65. Serpe CJ, Kohm AP, Huppenbauer CB, Sanders VM, Jones KJ. Exacerbation of facial motoneuron loss after facial nerve transection in severe combined immunodeficient (scid) mice. J Neurosci. 1999;19(11):RC7
  66. Novikov L, Novikova L, Kellerth JO. Brain-derived neurotrophic factor promotes survival and blocks nitric oxide synthase expression in adult rat spinal motoneurons after ventral root avulsion. Neurosci Lett. 1995;200(1):45–48
  67. Kishino A, Ishige Y, Tatsuno T, Nakayama C, Noguchi H. BDNF prevents and reverses adult rat motor neuron degeneration and induces axonal outgrowth. Exp Neurol. 1997;144(2):273–286
  68. Hammarberg H, Lidman O, Lundberg C, Eltayeb SY, Gielen AW, Muhallab S, et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci. 2000;20(14):5283–5291
  69. Mendel I, Kerlero de Rosbo N, Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol. 1995;25(7):1951–1959
  70. Kawakami N, Odoardi F, Ziemssen T, Bradl M, Ritter T, Neuhaus O, et al. Autoimmune CD4+ T cell memory: lifelong persistence of encephalitogenic T cell clones in healthy immune repertoires. J Immunol. 2005;175(1):69–81
  71. Burns J, Rosenzweig A, Zweiman B, Lisak RP. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol. 1983;81(2):435–440
  72. Neumann H, Misgeld T, Matsumuro K, Wekerle H. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc Natl Acad Sci U S A. 1998;95(10):5779–5784
  73. Lisak RP, Benjamins JA, Bealmear B, Yao B, Land S, Nedelkoska L, et al. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures. Mult Scler. 2006;12(2):149–168
  74. Lisak RP, Benjamins JA, Bealmear B, Nedelkoska L, Yao B, Land S, et al. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteins. J Neuroinflammation. 2007;4:30
  75. Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. EMBO J. 2000;19(6):1290–1300
  76. Kos CH. Cre/loxP system for generating tissue-specific knockout mouse models. Nutr Rev. 2004;62(6 Pt 1):243–246
  77. Linker R, Lee D-H, Siglienti I, Gold R. Is there a role for neurotrophins in the pathology of multiple sclerosis?. J Neurol. 2007;254(Suppl 1):33–40
  78. Huang R, Huang J, Cathcart H, Smith S, Poduslo SE. Genetic variants in brain-derived neurotrophic factor associated with Alzheimer's disease. J Med Genet. 2007;44(2):e66
  79. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112(2):257–269
  80. Bueller JA, Aftab M, Sen S, Gomez-Hassan D, Burmeister M, Zubieta J. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol Psychiatry. 2006;59(9):812–815
  81. Chen Z, Jing D, Bath KG, Ieraci A, Khan T, Siao C, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006;314(5796):140–143
  82. Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci. 2004;24(45):10099–10102
  83. Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet. 2002;71(3):651–655
  84. Neves-Pereira M, Cheung JK, Pasdar A, Zhang F, Breen G, Yates P, et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry. 2005;10(2):208–212
  85. Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, Kanazawa I, et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol. 2002;51(1):133–136
  86. Lindquist S, Schott BH, Ban M, Compston DAS, Sawcer S, Sailer M. The BDNF-Val66Met polymorphism: implications for susceptibility to multiple sclerosis and severity of disease. J Neuroimmunol. 2005;167(1–2):183–185
  87. Blanco Y, Gómez-Choco M, Arostegui JL, Casanova B, Martínez-Rodríguez JE, Boscá I, et al. No association of the Val66Met polymorphism of brain-derived neurotrophic factor (BDNF) to multiple sclerosis. Neurosci Lett. 2006;396(3):217–219
  88. Zivadinov R, Weinstock-Guttman B, Benedict R, Tamaño-Blanco M, Hussein S, Abdelrahman N, et al. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum Mol Genet. 2007;16(22):2659–2668
  89. Mirowska-Guzel D, Mach A, Gromadzka G, Czlonkowski A, Czlonkowska A. BDNF A196G and C270T gene polymorphisms and susceptibility to multiple sclerosis in the Polish population. Gender differences. J Neuroimmunol. 2008;193(1–2):170–172
  90. Liguori M, Fera F, Gioia MC, Valentino P, Manna I, Condino F, et al. Investigating the role of brain-derived neurotrophic factor in relapsing–remitting multiple sclerosis. Genes Brain Behav. 2007;6(2):177–183
  91. Weinstock-Guttman B, Zivadinov R, Tamaño-Blanco M, Abdelrahman N, Badgett D, Durfee J, et al. Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J Neuroimmunol. 2007;188(1–2):167–174
  92. Liguori M, Fera F, Patitucci A, Manna I, Condino F, Valentino P, et al. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing–remitting multiple sclerosis. Brain Res. 2009;1256:123–128
  93. Hashimoto T, Lewis DA. BDNF Val66Met polymorphism and GAD67 mRNA expression in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry. 2006;163(3):534–537
  94. Tramontina J, Frey BN, Andreazza AC, Zandona M, Santin A, Kapczinski F. Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder. Mol Psychiatry. 2007;12(3):230–231
  95. Sarchielli P, Greco L, Stipa A, Floridi A, Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol. 2002;132(1–2):180–188
  96. Gielen A, Khademi M, Muhallab S, Olsson T, Piehl F. Increased brain-derived neurotrophic factor expression in white blood cells of relapsing–remitting multiple sclerosis patients. Scand J Immunol. 2003;57(5):493–497
  97. Petereit HF, Lindemann H, Schoppe S. Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor. Mult Scler. 2003;9(1):16–20
  98. Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C, et al. Neurotrophic factors and clinical recovery in relapsing–remitting multiple sclerosis. Scand J Immunol. 2005;62(2):176–182
  99. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood–brain barrier. Neuropharmacology. 1999;37(12):1553–1561
  100. Deloire-Grassin MS, Brochet B, Quesson B, Delalande C, Dousset V, Canioni P, et al. In vivo evaluation of remyelination in rat brain by magnetization transfer imaging. J Neurol Sci. 2000;178(1):10–16
  101. Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol. 2007;61(4):300–306
  102. Goodin DS. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology. 2008;71(24 Suppl 3):S8–S13
  103. Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A. 2003;100(24):14157–14162
  104. Aharoni R, Herschkovitz A, Eilam R, Blumberg-Hazan M, Sela M, Bruck W, et al. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2008;105(32):11358–11363
  105. Teitelbaum D, Aharoni R, Klinger E, Kreitman R, Raymond E, Malley A, et al. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies. Ann N Y Acad Sci. 2004;1029:239–249
  106. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001;49(3):290–297
  107. Dabbert D, Rösner S, Krämer M, Schöll U, Tumani H, Mäder M, et al. Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. Neurosci Lett. 2000;289(3):205–208
  108. Ziemssen T, Schrempf W. Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol. 2007;79:537–570
  109. Blanco Y, Moral EA, Costa M, Gómez-Choco M, Torres-Peraza JF, Alonso-Magdalena L, et al. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study. Neurosci Lett. 2006;406(3):270–275
  110. Azoulay D, Vachapova V, Shihman B, Miler A, Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol. 2005;167(1–2):215–218Ott
  111. Picard-Riera N, Decker L, Delarasse C, Goude K, Nait-Oumesmar B, Liblau R, et al. Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice. Proc Natl Acad Sci U S A. 2002;99(20):13211–13216
  112. Bermel RA, Rudick RA. Interferon-beta treatment for multiple sclerosis. Neurotherapeutics. 2007;4(4):633–646
  113. Biernacki K, Antel JP, Blain M, Narayanan S, Arnold DL, Prat A. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol. 2005;62(4):563–568
  114. Maier K, Kuhnert AV, Taheri N, Sättler MB, Storch MK, Williams SK, et al. Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study. Am J Pathol. 2006;169(4):1353–1364
  115. Lalive PH, Kantengwa S, Benkhoucha M, Juillard C, Chofflon M. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. J Neuroimmunol. 2008;197(2):147–151
  116. Azoulay D, Mausner-Faimberg K, Urshansky N, Fahoum F, Karni A. Interferon- therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism. J Neuroimmunol. 2009;211:114–119
  117. Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C, et al. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin Immunol. 2006;118(1):77–82
  118. Hamamcioglu K, Reder AT. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler. 2007;13(4):459–470
  119. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15(11):7539–7547
  120. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452
  121. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther. 2001;92(1):57–70
  122. Wesselborg S, Janssen O, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol. 1993;150(10):4338–4345
  123. Macchi B, Matteucci C, Nocentini U, Caltagirone C, Mastino A. Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis. Neuroreport. 1999;10(2):399–402
  124. Zang YC, Kozovska MM, Hong J, Li S, Mann S, Killian JM, et al. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur J Immunol. 1999;29(5):1692–1700
  125. Pender MP. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet. 1998;351(9107):978–981
  126. Zipp F. Apoptosis in multiple sclerosis. Cell Tissue Res. 2000;301(1):163–171
  127. Pette M, Fujita K, Kitze B, Whitaker JN, Albert E, Kappos L, et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology. 1990;40(11):1770–1776
  128. Saresella M, Marventano I, Speciale L, Ruzzante S, Trabattoni D, Della Bella S, et al. Programmed cell death of myelin basic protein-specific T lymphocytes is reduced in patients with acute multiple sclerosis. J Neuroimmunol. 2005;166(1–2):173–179
  129. Okuda Y, Apatoff BR, Posnett DN. Apoptosis of T cells in peripheral blood and cerebrospinal fluid is associated with disease activity of multiple sclerosis. J Neuroimmunol. 2006;171(1–2):163–170
  130. Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 1995;373(6513):438–441
  131. Zipp F, Faber E, Sommer N, Müller C, Dichgans J, Krammer PH, et al. CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis. No differences from normal individuals and no relation to HLA-DR2. J Neuroimmunol. 1998;81(1–2):168–172
  132. Zipp F, Weller M, Calabresi PA, Frank JA, Bash CN, Dichgans J, et al. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing–remitting multiple sclerosis. Ann Neurol. 1998;43(1):116–120
  133. Friese MA, Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?. Brain. 2005;128(Pt 8):1747–1763
  134. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med. 2000;192(3):393–404
  135. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlén C, Goverman J. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med. 2001;194(5):669–676
  136. Perez-Pinera P, Hernandez T, García-Suárez O, de Carlos F, Germana A, Del Valle M, et al. The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas. Mol Cell Biochem. 2007;295(1–2):19–26
  137. Lazarovici P, Rasouly D, Friedman L, Tabekman R, Ovadia H, Matsuda Y. K252a and staurosporine microbial alkaloid toxins as prototype of neurotropic drugs. Adv Exp Med Biol. 1996;391:367–377
  138. Aharoni R, Eilam R, Domev H, Labunskay G, Sela M, Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A. 2005;102(52):19045–19050

PII: S0022-510X(09)00836-3

doi: 10.1016/j.jns.2009.08.057

Journal of the Neurological Sciences
Volume 287, Issue 1 , Pages 17-26 , 15 December 2009

Article Tools

* Image Usage & Resolution